- Home
- DSY vs TCRX Comparison
DSY vs TCRX Comparison
Compare DSY & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- TCRX
- Stock Information
- Founded
- DSY 2020
- TCRX 2018
- Country
- DSY China
- TCRX United States
- Employees
- DSY N/A
- TCRX N/A
- Industry
- DSY
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- TCRX Health Care
- Exchange
- DSY Nasdaq
- TCRX Nasdaq
- Market Cap
- DSY 110.7M
- TCRX 115.8M
- IPO Year
- DSY N/A
- TCRX 2021
- Fundamental
- Price
- DSY $2.17
- TCRX $2.17
- Analyst Decision
- DSY
- TCRX Strong Buy
- Analyst Count
- DSY 0
- TCRX 5
- Target Price
- DSY N/A
- TCRX $11.40
- AVG Volume (30 Days)
- DSY 106.0K
- TCRX 373.5K
- Earning Date
- DSY 02-10-2025
- TCRX 03-05-2025
- Dividend Yield
- DSY N/A
- TCRX N/A
- EPS Growth
- DSY 120.37
- TCRX N/A
- EPS
- DSY 0.01
- TCRX N/A
- Revenue
- DSY $7,323,356.00
- TCRX $9,362,000.00
- Revenue This Year
- DSY N/A
- TCRX N/A
- Revenue Next Year
- DSY N/A
- TCRX $5.14
- P/E Ratio
- DSY $166.38
- TCRX N/A
- Revenue Growth
- DSY 16.37
- TCRX N/A
- 52 Week Low
- DSY $0.75
- TCRX $1.99
- 52 Week High
- DSY $13.47
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- DSY 48.11
- TCRX 37.12
- Support Level
- DSY $1.79
- TCRX $2.02
- Resistance Level
- DSY $2.20
- TCRX $2.17
- Average True Range (ATR)
- DSY 0.38
- TCRX 0.16
- MACD
- DSY 0.08
- TCRX 0.02
- Stochastic Oscillator
- DSY 67.33
- TCRX 26.47
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.